All In Biotech

Drug Trial Radar · NCT00240747

Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients

Last checked: Nov 19, 2026Latest source record: May 25, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

Not stated

Start

Jun 2000

Primary completion

Not stated

Study completion Jan 2005

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Aventis Pharmaceuticals
First posted
Oct 18, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 27 weeks, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label, multicenter, multiple-dose, study of population pharmacokinetics of I.V. Synercid (7.5 mg/kg every 8 hours) in 75 pediatric patients. The purpose is to assess the population pharmacokinetics of Synercid in pediatric patients and to collect additional safety and efficacy data in pediatric patients.

Conditions

  • Gram-Positive Bacterial Infections

Interventions

  • SynercidDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Population pharmacokinetics

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • Duke University Medical Center

    Durham, North Carolina

  • Children's Hospital

    Cincinnati, Ohio

  • The Cleveland Clinic

    Cleveland, Ohio

  • Children's Hospital at Saint Francis

    Tulsa, Oklahoma

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.